Lexicon Genetics Incorporated has granted a non-exclusive sublicense to Bristol- Myers Squibb Company for the use of certain aspects of Lexicon’s positive-negative selection and isogenic DNA technologies.
Bristol-Myers Squibb will use the technology for the generation of knockout mice for internal research purposes to gain predictive information about gene products that are valid drug targets or therapeutic proteins for drug development.
Financial terms were not disclosed.
“We are pleased that Bristol-Myers Squibb has selected Lexicon’s technologies for gene targeting and has joined our growing list of sublicensees,” stated Randall B. Riggs, Senior Vice President of Business Development at Lexicon Genetics. “The use of our technologies will further advance Bristol-Myers Squibb’s internal drug discovery and therapeutic validation efforts.”
“We believe that Lexicon’s gene targeting technologies will play a significant role in advancing our drug discovery and target validation efforts,” said Elliott Sigal, M.D., Ph.D., Senior Vice President, Early Discovery and Applied Technology.
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology.
Complementary to its gene-specific custom knockout technology, Lexicon has invented high-throughput genome-wide gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of knockout mouse clones.
Bristol-Myers Squibb is a $20 billion diversified global health and personal care company whose mission is to extend and enhance human life.